机械循环支持后的运动能力与心脏移植相比,在晚期心力衰竭中
Hui Zhen Lo1, Louise Fuller2, Peter Bergin3,4
1Peninsula Health, Frankston, Victoria, Australia.
JHLT open
|February 9, 2026
概括
心室辅助器件 (VAD) 和正心移植 (OHTx) 在晚期心力衰竭患者中提供类似的运动能力. 性别显著影响OHTx接受者的运动能力,而不是VAD桥梁.
科学领域:
- 心脏病学 心脏病学
- 移植医学 移植医学
- 机械循环支持 机械循环支持
背景情况:
- 晚期心力衰竭患者经常接受正心移植 (OHTx) 或心室辅助器件 (VAD) 植入.
- 通常认为OHTx比VAD产生更高的运动能力,但这种比较缺乏正式调查.
研究的目的:
- 评估和比较VAD植入后患者的运动能力与OHTx.
- 在这些患者群体中确定运动能力的预测因素.
主要方法:
- 一个回顾性单中心队列研究包括78名在2022年1月至2024年1月期间接受OHTx或VAD的患者.
- 使用6分钟步行测试 (6MWT) 评估了运动能力.
- 多变量线性回归分析了6MWT预测的并发症和干预类型,并作为共变量添加了显著因素.
主要成果:
- 最大6MWT在OHTx (中位数为534.0m) 和VAD (中位数为608.5m) 队列 (p=0.30) 之间是相似的.
- 性别在OHTx队列 (β=-69.1,p<0.02) 中是一个显著的预测因素,并在VAD队列 (β=-199,p<0.09) 中显示出趋势.
- 在OHTx患者中,VAD桥梁没有预测3个月的6MWT (p=0.99),在联合队列中,VAD和OHTx都没有预测6MWT (p=0.88). 总停留时间是一个显著的预测指标 (p<0.0001).
结论:
- VAD和OHTx与晚期心力衰竭中可比的运动能力有关.
- 作为OHTx桥梁的VAD植入不会对移植后的运动能力产生负面影响.
- 性别成为OHTx接受者的运动能力的主要预测因素.
关键词:
能力行使能力的行使能力.心脏衰竭是因为心脏衰竭.机械循环支持 机械循环支持在心脏移植的过程中,心脏的正体移植 (orthotopic heart transplant) 是一种方法.腹腔室辅助器件可以帮助心室.更多相关视频
04:20Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
6.3K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
相关概念视频
Heart Failure II: Pathophysiology
987
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
987
Pathophysiology of Heart Failure
3.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction
937
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
937
Heart Failure VI: Adjunct Therapies
385
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
385
Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management
352
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
352
